Skip to main content
. 2020 Sep 30;11:575488. doi: 10.3389/fimmu.2020.575488

FIGURE 6.

FIGURE 6

Immune modulatory UC-MSC activate T cell regulatory pathways leading to reduction of activated T cells. (A) Flow cytometry analyses and percentages of naïve (NAÏVE, CD45RA+/CD62L+), central memory (TCM, CD45RA–/CD62L+), effector memory (TEM, CD45RA–/CD62L–), and terminal effector (TEMRA, CD45RA+/CD62L–) T lymphocyte subsets in CD3+/CD4+ and CD3+/CD8+ T cell populations in PBMNC or PBMNC/UC-MSC cocultures activated with PHA or αCD3/CD28 for 5 days (* vs. Control, p < 0.05, n = 3–5). (B) Expression of Programmed cell death protein ligand 1 (PD-L1) and 2 (PD-L2) in UC-MSC, assessed by flow cytometry following 5 days of treatment with PHA, αCD3/CD28, TNFα/IL1b (CK), PHA and αCD3/CD28-activated PBMNC/MSC (# vs. Control, p < 0.05, n = 6–8). (C) Programmed cell death protein 1 (PD-1) expression in CD3+ T cells 5 days stimulation with PHA, αCD3/CD28, TNFα/IL1b (CK), PHA and αCD3/CD28-activated PBMNC/MSC (# vs. Control, p < 0.05, n = 3–5).